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Abstract 26 
Whilst Pseudomonas aeruginosa (PA) cross-infection is well-documented amongst cystic 27 
fibrosis (CF) patients, the equivalent risk amongst non-CF bronchiectasis (NCFB) patients is 28 
unclear, particularly those managed alongside CF patients. We performed analysis of PA 29 
within a single centre that manages an unsegregated NCFB cohort alongside a segregated CF 30 
cohort. We found no evidence of cross-infection between the two cohorts, nor within the 31 
segregated CF cohort. However, within the unsegregated NCFB cohort, evidence of cross-32 
infection was found between three (of 46) patients. Whilst we do not presently advocate any 33 
change in the management of our NCFB cohort, longitudinal surveillance is clearly warranted. 34 
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Pseudomonas aeruginosa (PA) is a significant pathogen within cystic fibrosis (CF) and non-35 
cystic fibrosis bronchiectasis (NCFB) cohorts. Transmissibility of PA amongst CF patients has 36 
been widely-documented,[1] leading to widespread segregation policies.[2] In contrast, the 37 
cross-infection risk amongst NCFB patients is unclear. One UK study concluded that PA cross-38 
infection was rare in NCFB.[3] However, in that study, NCFB patients were managed at a 39 
different site from the local CF cohort. Similarly, a recent multi-centre study highlighted the 40 
potential for PA cross-infection, although this was again exclusively focused on NCFB 41 
cohorts.[4] In many hospitals, including ours, CF and NCFB patients share facilities and 42 
healthcare professionals. In this context, we conducted a cross-sectional study of PA within 43 
our NCFB and CF cohorts to assess the likelihood of cross-infection. In parallel, analysis of 44 
local non-respiratory isolates allowed comparison with PA in the wider population. 45 
Sixty-three NCFB and 32 CF patients were recruited from out-patient clinics based on a 46 
documented diagnosis of NCFB/CF and previous PA-positive sputum. PA was subsequently 47 
obtained from 46/63 NCFB and 22/32 CF patients. Ten representative colonies were stored 48 
from each PA-positive sputum, and were initially genotyped by Random Amplification of 49 
Polymorphic DNA (RAPD)[5], ahead of Multi-Locus Sequence Typing (MLST).[6] In brief, 50 
RAPD was performed on all 10 isolates per patient, and all unique profiles underwent 51 
additional evaluation using microfluidic amplicon separation and cluster analysis as described 52 
previously.[7] This same panel of isolates with unique RAPD profiles was subjected to MLST, 53 
enabling strain identification in a global context. Patient demographics and methodologies are 54 
detailed in online supporting information. 55 
Through this approach, 25/46 NCFB patients (54%) and 13/22 CF patients (59%) were found 56 
to harbour their own unique strain by MLST. The remaining patients harboured strains that 57 
were shared within or between cohorts (Table 1).  58 
 59 
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Table 1. Shared strains of Pseudomonas aeruginosa identified within the respiratory (CF and 60 
NCFB) and non-respiratory cohorts, as defined by MLST. One NCFB patient was co-infected 61 
with ST17 and ST564. Isolates in the non-respiratory cohort originated from genitourinary, 62 
wound, ENT and faecal samples from community and hospital investigation.  63 
 64 
MLST type Alias 
NCFB  
(n=46) 
CF  
(n=22) 
Non-resp  
(n=76) 
Total 
(n=144) 
ST17 Clone C 8 (17%)  7 (9%) 15 (10%) 
ST27  1 (2%) 3 (14%) 5 (7%) 9 (6%) 
ST146 LES  2 (9%)  2 (1%) 
ST235  1 (2%) 1 (5%)  2 (1%) 
ST252  3 (7%) 1 (5%)  4 (3%) 
ST253 PA14 2 (4%)  10 (13%) 12 (8%) 
ST274  1 (2%) 1 (5%) 2 (3%) 4 (3%) 
ST395  3 (7%) 1 (5%) 3 (4%) 7 (5%) 
ST564  3 (7%)   3 (2%) 
 65 
 66 
All shared strains within our respiratory cohorts are globally-distributed according to the 67 
MLST database, and the majority have been isolated from diverse clinical and environmental 68 
sources. Consistent with this, we observed many of the same strains within our non-respiratory 69 
cohort (Table 1). Given the ubiquitous nature of these strains, their presence in multiple patients 70 
may reflect independent acquisition rather than cross-infection, and neither RAPD nor MLST 71 
provide sufficient resolution to address this. Consequently, whole genome sequencing (WGS) 72 
was performed on the shared strains from the respiratory cohorts to assess relatedness at a 73 
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whole-genome level. For ST17 (the most prevalent strain observed), three isolates per patient 74 
were sequenced to enable assessment of inter- and intra-patient diversity. For all other shared 75 
strains, one isolate was sequenced per patient.  76 
In WGS-based studies, patient-to-patient transmission cannot be defined based on a simple 77 
threshold of the number of single nucleotide polymorphisms (SNPs) between isolates. 78 
Hypermutation accelerates genetic divergence, and hypermutable PA are commonly observed 79 
within chronic lung infections.[8] Consistent with this, in silico prediction of hypermutators 80 
revealed putative hypermutable PA within our respiratory cohorts (online supporting 81 
information) and predicted hypermutator status correlated strongly with SNP distance (Fig. 82 
1B), highlighting the difficulty in setting a SNP threshold. Consequently, to aid interpretation, 83 
we incorporated relevant publicly-available genome sequences into our WGS-based analysis, 84 
enabling us to compare PA isolates from our respiratory cohorts with representative PA that 85 
belong to the same sequence type but are not epidemiologically-linked to our cohorts (see 86 
online supporting information). Furthermore, when considering likelihood of cross-infection, 87 
relevant patient-specific and strain-specific information was reviewed, including potential 88 
cross-infection events, duration of infection, change in culture status and knowledge of strain 89 
distribution and transmissibility. 90 
The WGS analysis revealed that the CF and NCFB isolates belonging to ST17, ST27, ST235, 91 
ST252, ST253, ST274 and ST395 are as divergent from each other (Fig. 1A; circles) as they 92 
are from unconnected representatives of the same sequence type (Fig. 1A; grey crosses). 93 
Furthermore, with the exception of two intra-patient pairwise comparisons (one involving a 94 
predicted hypermutator), analysis of the ST17 isolates revealed significantly greater ST17 95 
diversity between patients than within patients. Whilst cross-infection cannot be completely 96 
ruled out, particularly for the divergent ST17 group, we conclude (on the basis of inter-patient 97 
diversity, the ubiquitous nature of these strains and a review of relevant clinical information) 98 
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that the occurrence of these seven sequence types in multiple patients most likely reflects 99 
independent acquisition. 100 
In contrast, two shared strains exhibited low inter-patient diversity that we believe to be 101 
indicative of cross-infection. Firstly, two CF isolates of ST146 (Liverpool epidemic strain, 102 
LES) differed by only 31 SNPs, and were more closely-related to each other than to 103 
unconnected representatives of the LES (Fig. 1A). The two patients involved were siblings who 104 
had become colonised with PA before coming under the care of our unit. The genetic 105 
relatedness of the isolates coupled with the high level of personal contact between patients and 106 
the known transmissibility of LES strongly supports cross-infection.  107 
More significantly, the ST564 isolates from three unrelated NCFB patients are near-identical, 108 
differing by only 4-12 SNPs. Whilst no publicly-available genomes of ST564 representatives 109 
were available for comparison, we believe this extremely high level of genetic relatedness is 110 
indicative of cross-infection, a conclusion further supported by clinical records that revealed 111 
two of the three patients shared a waiting area and lung function room approximately 17 months 112 
prior to recruitment. This potential cross-infection event did not coincide with a clear change 113 
in PA culture status as one of the patients intermittently isolated PA before and after this event 114 
whilst the other patient had evidence of multiple PA strains (and therefore super-infection may 115 
have occurred). Whilst we were unable to identify potential cross-infection event(s) involving 116 
the third ST564-infected patient (who also carried multiple strains), a difference of only 4 SNPs 117 
strongly supports cross-infection. Interactions may have occurred in or outside the hospital that 118 
are not apparent via the review of clinical notes. Furthermore, we believe ST564 acquisition 119 
from a common environmental source is highly unlikely due to its absence from other cohorts.  120 
In agreement with previous literature,[3] but expanding it to high-resolution WGS analysis, we 121 
therefore conclude that PA cross-infection is highly likely to have occurred within our NCFB 122 
cohort. Whilst we believe this to be restricted to ST564, additional cross-infection events 123 
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involving other sequence types cannot be definitively ruled out, particularly given the 124 
confounding role of hypermutators. Similarly, on the balance of evidence, we consider it 125 
unlikely that cross-infection has occurred between CF and NCFB cohorts despite them sharing 126 
facilities, and notable differences in strain distribution between the cohorts argue against the 127 
presence of an environmental reservoir within the unit. Our studies suggest that ST564 has the 128 
potential for transmissibility and super-infection. Although not reported in the literature, the 129 
MLST database (https://pubmlst.org/paeruginosa; [9]) reports ST564 as having been isolated 130 
from sputum (Netherlands) and water (Australia and France).  131 
At present, we believe the negative impacts that would be associated with implementing a 132 
segregated NCFB cohort (including reduced patients per clinic and reduced access to 133 
pulmonary rehabilitation courses) outweigh the low risk of cross-infection. However, with 134 
growing NCFB cohorts nationwide[10] and cross-infection possible, ongoing longitudinal 135 
surveillance is clearly warranted. 136 
 137 
Acknowledgements 138 
The authors would like to thank all the patients who participated in this study; Hilary Mortimer, 139 
Sarah Murray, Rachel Rogers, Jayne Trott, Roseanne Lowless and Miriam Green for their help 140 
in obtaining samples; the Microbiology Department at the Royal Devon & Exeter Hospital, 141 
particularly Nigel Richardson and Dr Cressida Auckland; and Dr Matthew Robinson and 142 
Audrey Farbos for laboratory guidance. The authors acknowledge use of the University of 143 
Exeter’s Zeus computational infrastructure for analysis of whole genome sequence data. The 144 
project was supported by NIHR Exeter Clinical Research Facility, and the authors thank Chloe 145 
Slade and Kathryn Shears for their assistance in managing samples and data.  146 
Competing Interests 147 
8 
 
EM declares a grant from AlgiPharma AS held as a service contract on a CF clinical trial 148 
(unrelated to this work).  149 
Funding 150 
This study was funded though charitable donations and a Small Grants Award by the Research 151 
& Development department at the Royal Devon & Exeter NHS Foundation Trust. The funding 152 
sources had no input into this study or its submission for publication.  153 
Contributors 154 
Study Concept & Design, CDS, NJW, PJM & ARB; Patient recruitment, PJM, NJW & CDS; 155 
Methodology & Investigation, PJM, JR & KAM; Data Analysis & Interpretation, PJM, ARB, 156 
MJB, EM, PAO & KP; Writing – Original Draft, ARB & PJM; Writing – Review & Editing, 157 
CDS, NJW, CJS, EM, MJB, ARB & PJM. 158 
Ethics approval 159 
Ethical approval for the study of our NCFB cohort was obtained through the NRES Committee 160 
South West- Exeter (14/SW/0080). Our CF samples and data were collected through the RD&E 161 
tissue bank (11/SW/0018).  162 
Provenance and peer review 163 
Not commissioned 164 
 165 
References 166 
 1.  Fothergill JL, Walshaw MJ, Winstanley C. Transmissible strains of Pseudomonas 167 
aeruginosa in cystic fibrosis lung infections. Eur Respir J 2012;40:227-238.  168 
 2.  Saiman L, Siegel JD, LiPuma JJ et al. Infection prevention and control guideline for 169 
cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35:S1-S67.  170 
 3.  De Soyza A, Perry A, Hall AJ et al. Molecular epidemiological analysis suggests cross-171 
infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis. 172 
Eur Respir J 2014;43:900-903.  173 
9 
 
 4.  Hilliam Y, Moore MP, Lamont IL et al. Pseudomonas aeruginosa adaptation and 174 
diversification in the non-cystic fibrosis bronchiectasis lung. Eur Respir J 175 
2017;49:1602108. 176 
 5.  Mahenthiralingam E, Campbell ME, Foster J et al. Random amplified polymorphic 177 
DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic 178 
fibrosis. J Clin Microbiol 1996;34:1129-1135. 179 
 6.  Curran B, Jonas D, Grundmann H et al. Development of a multilocus sequence typing 180 
scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol 181 
2004;42:5644-5649. 182 
 7.  White J, Gilbert J, Hill G et al. Culture-independent analysis of bacterial fuel 183 
contamination provides insight into the level of concordance with the standard industry 184 
practice of aerobic cultivation. Appl Environ Microbiol 2011;77:4527-4538.  185 
 8.  Macia MD, Blanquer D, Togores B et al. Hypermutation is a key factor in development 186 
of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing 187 
chronic lung infections. Antimicrob Agents Chemother 2005;49:3382-3386. 188 
 9.  Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the 189 
population level. BMC Bioinformatics 2010;11:595.  190 
 10.  Quint JK, Millett ER, Joshi M et al. Changes in the incidence, prevalence and mortality 191 
of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur 192 
Respir J 2016;47:186-193.  193 
 194 
 195 
Figure legends 196 
Figure 1. Genetic diversity within P. aeruginosa isolates, as defined by whole genome 197 
sequencing. (A) The number of single nucleotide polymorphisms (SNPs) was calculated across 198 
the core genome of all sequenced isolates. Each data point represents a pairwise comparison 199 
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within each ST, with the bar representing the mean. Circles represent pairwise comparisons 200 
that are exclusively between PA isolates from our own respiratory cohort (CF or NCFB), with 201 
the open circles representing those comparisons in which at least one isolate is a predicted 202 
hypermutator. The grey crosses represent pairwise comparisons in which one isolate is from 203 
our respiratory cohort and the other is an unconnected representative of the same sequence type 204 
(using publicly-available genomes). For ST17, SNP numbers are shown that reflect the 205 
diversity observed between patients (ST17-inter) and within individual patients (ST17-intra; 206 
based on sequencing of three isolates per patient). (B) Predicted hypermutable PA isolates 207 
exhibited significantly elevated levels of genetic divergence (SNP distance) relative to 208 
predicted non-hypermutable PA. 209 
  210 
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